279 related articles for article (PubMed ID: 2212119)
1. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
Lecavalier MA; From L; Gaid N
J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
[TBL] [Abstract][Full Text] [Related]
2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
3. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas.
Spałkowska M; Dyduch G; Broniatowska E; Damiani G; Wojas-Pelc A
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833446
[No Abstract] [Full Text] [Related]
4. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
[TBL] [Abstract][Full Text] [Related]
5. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
Schubert C; Parwaresch R; Rudolph P
Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
[TBL] [Abstract][Full Text] [Related]
6. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
7. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
8. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors in melanocytic lesions. Occurrence in patients with dysplastic nevus syndrome.
Ellis DL; Wheeland RG; Solomon H
Arch Dermatol; 1985 Oct; 121(10):1282-5. PubMed ID: 4037821
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
11. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
12. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
[TBL] [Abstract][Full Text] [Related]
13. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
14. Melanocytic lesions in a private pathology practice. Comparison of histologic features in different tumor types with particular reference to dysplastic nevi.
Hastrup N; Hou-Jensen K
APMIS; 1993 Nov; 101(11):845-50. PubMed ID: 8286092
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
16. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
Cockerell CJ; Berson DS
Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
[TBL] [Abstract][Full Text] [Related]
17. Oestrogen receptor-beta expression in melanocytic lesions.
Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
[TBL] [Abstract][Full Text] [Related]
18. Expression and distribution of transforming growth factor-alpha within melanocytic lesions.
Nanney LB; Coffey RJ; Ellis DL
J Invest Dermatol; 1994 Nov; 103(5):707-14. PubMed ID: 7963661
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
20. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
